For US healthcare professionals only

Important Safety Information | Prescribing Information | Patient Support | Celltrion USA | Patient Site

For US healthcare professionals only

Prescribing Information

ZYMFENTRA offers patients biweekly administration for maintaining remission1

4 weeks after the last administration of IV infliximab shift to biweekly administration of ZYMFENTRA™

IV Induction Chart ZYMFENTRA™

After the last administration of IV infliximab shift to biweekly ZYMFENTRA in place of the next scheduled IV infusion

IFX IV Maintenance Schedule
Divider Arc 1

ZYMFENTRA offers a streamlined treatment regimen that liberates patients from infusion burdens1

Zymfentra Pen Attributes Diagram

ZYMFENTRA offers a streamlined treatment regimen that liberates patients from infusion burdens1

ZYMFENTRA gives patients increased flexibility and convenience through self administration—more freedom, less restraints

The first and only subcutaneous infliximab formulation approved by the FDA1,2

Increased flexibility and convenience with biweekly self administration

Convenient 2-step injection process

Comparable efficacy and safety following IV induction with an infliximab production

Sterile, preservative-free, citrate-free solution

Latex-free

Zymfentra Pen Vertical
Divider Arc 2

How to inject ZYMFENTRA

Play this video for step-by-step instructions on how your patients or their caregivers should inject ZYMFENTRA.

Storage and handling1

  • Store refrigerated at 2°C to 8°C (36°F to 46°F)
  • If needed, the product may be stored at room temperature at 20°C to 25°C (68°F to 77°F) for up to 14 days
    • Once the product has been stored at room temperature, it should not be placed back into the refrigerator
    • The product must be discarded if not used within the 14 days
  • DO NOT FREEZE
  • Keep the product in its outer carton until time of administration in order to protect from light

IFX=infliximab; IV=intravenous.

References: 1. ZYMFENTRA™ Prescribing Information, Celltrion, Inc., 2023. Celltrion USA, Inc.  2. Data on file. Celltrion, Inc. 

Important Safety Information

WARNING: SERIOUS INFECTIONS and MALIGNANCY

Contraindications

Warnings and Precautions

Common Adverse Reactions (≥3%)

Drug Interactions

For more information, see full Prescribing Information including BOXED WARNING.